BR112014009282A8 - ácido de meldrum, ácido barbitúrico e derivados de pirazolona substituída com hidroxilamina como doadores de hno - Google Patents

ácido de meldrum, ácido barbitúrico e derivados de pirazolona substituída com hidroxilamina como doadores de hno Download PDF

Info

Publication number
BR112014009282A8
BR112014009282A8 BR112014009282A BR112014009282A BR112014009282A8 BR 112014009282 A8 BR112014009282 A8 BR 112014009282A8 BR 112014009282 A BR112014009282 A BR 112014009282A BR 112014009282 A BR112014009282 A BR 112014009282A BR 112014009282 A8 BR112014009282 A8 BR 112014009282A8
Authority
BR
Brazil
Prior art keywords
acid
compounds
disease
hydroxylamine
pharmaceutical compositions
Prior art date
Application number
BR112014009282A
Other languages
English (en)
Other versions
BR112014009282B1 (pt
BR112014009282A2 (pt
Inventor
a guthrie Daryl
p toscano John
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of BR112014009282A2 publication Critical patent/BR112014009282A2/pt
Publication of BR112014009282A8 publication Critical patent/BR112014009282A8/pt
Publication of BR112014009282B1 publication Critical patent/BR112014009282B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

resumo ácido de meldrum, ácido barbitúrico e derivados de pirazol substituídos com hidroxilamina como doadores de hno o objeto revelado proporciona certos compostos n-substituídos derivados de hidroxilamina, composições farmacêuticas e kits compreendendo estes compostos, e métodos de utilização de tais compostos ou composições farmacêuticas. em particular, o objeto revelado proporciona métodos de utilização de tais compostos ou de composições farmacêuticas para tratar, prevenir, ou retardar o aparecimento e/ou o desenvolvimento de uma doença ou condição. em algumas formas de realização, a doença ou condição é selecionada de doenças cardiovasculares, isquemia, lesão de reperfusão, doença cancerosa, a hipertensão pulmonar e condições que respondem a terapia de nitroxilo.
BR112014009282-6A 2011-10-17 2012-10-16 Composto, composição farmacêutica contendo-o e uso do mesmo BR112014009282B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548036P 2011-10-17 2011-10-17
US61/548,036 2011-10-17
PCT/US2012/060425 WO2013059194A1 (en) 2011-10-17 2012-10-16 Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors

Publications (3)

Publication Number Publication Date
BR112014009282A2 BR112014009282A2 (pt) 2017-06-13
BR112014009282A8 true BR112014009282A8 (pt) 2020-04-22
BR112014009282B1 BR112014009282B1 (pt) 2021-12-14

Family

ID=47143299

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014009282-6A BR112014009282B1 (pt) 2011-10-17 2012-10-16 Composto, composição farmacêutica contendo-o e uso do mesmo

Country Status (13)

Country Link
US (3) US9181213B2 (pt)
EP (1) EP2776402B1 (pt)
JP (1) JP6177246B2 (pt)
KR (1) KR102061537B1 (pt)
CN (2) CN108409662B (pt)
AU (2) AU2013201929B2 (pt)
BR (1) BR112014009282B1 (pt)
CA (1) CA2852914C (pt)
HK (1) HK1200168A1 (pt)
IL (1) IL232101A (pt)
MX (1) MX363306B (pt)
SG (1) SG11201401587QA (pt)
WO (1) WO2013059194A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201401587QA (en) 2011-10-17 2014-07-30 Univ Johns Hopkins Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
EP3567031A1 (en) 2013-01-18 2019-11-13 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors with improved therapeutic index
WO2015109210A1 (en) 2014-01-17 2015-07-23 Cardioxyl Pharmaceuticals, Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
WO2015183839A1 (en) 2014-05-27 2015-12-03 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
EP3148983A1 (en) 2014-05-27 2017-04-05 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
WO2016210392A1 (en) * 2015-06-26 2016-12-29 The Johns Hopkins University N-substituted hydroxamic acids with carbon-based leaving groups as efficient hno donors and uses thereof
CN108473439B (zh) * 2015-10-19 2022-03-15 卡尔迪奥克斯尔制药公司 作为硝酰基供体的吡唑啉酮衍生物
CN108368038A (zh) 2015-10-19 2018-08-03 卡尔迪奥克斯尔制药公司 作为硝酰基供体的n-羟基磺酰胺衍生物
KR20190070912A (ko) * 2016-07-28 2019-06-21 더 존스 홉킨스 유니버시티 O-치환된 히드록삼산
MX2019008000A (es) 2017-01-03 2019-11-05 Cardioxyl Pharmaceuticals Inc Metodo de administracion de compuestos donadores de nitroxilo.
WO2019226213A2 (en) 2018-03-08 2019-11-28 Incyte Corporation AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US11912647B2 (en) 2020-05-22 2024-02-27 University Of Georgia Research Foundation, Inc. Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
ATE66143T1 (de) 1985-01-11 1991-08-15 Abbott Lab Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
CN1127492C (zh) 1997-10-24 2003-11-12 盐野义制药株式会社 抗风湿剂
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6638534B1 (en) 1998-07-28 2003-10-28 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
WO2005074598A2 (en) 2004-01-30 2005-08-18 Johns Hopkins University Nitroxyl progenitor compounds and methods of use
WO2006086188A2 (en) 2005-01-31 2006-08-17 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
WO2007002444A1 (en) 2005-06-23 2007-01-04 Johns Hopkins University Thiol-sensitive positive inotropes
TR200807066T1 (tr) 2006-03-17 2009-11-23 Johns Hopkins University School Of Medicine Fizyolojik açıdan kullanışlı nıtroksıl donorleri olarak yeni n-htdroksilsülfonamid türevleri
CA2648384A1 (en) 2006-04-13 2007-10-25 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
SG10201602375PA (en) 2007-09-26 2016-05-30 Univ Johns Hopkins N-Hydroxylsulfonamide Derivatives As New Physiologically Useful Nitroxyl Donors
CN102076342B (zh) 2008-05-07 2015-06-10 卡尔迪奥克斯尔制药公司 作为硝酰基供体的新亚硝基化合物及其使用方法
US20110160200A1 (en) 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
CN102753520B (zh) 2009-12-07 2016-06-08 约翰斯霍普金斯大学 N-酰氧基磺酰胺和n-羟基-n-酰基磺酰胺衍生物
CA2782248A1 (en) 2009-12-07 2011-06-16 Cardioxyl Pharmaceuticals, Inc. Bis-acylated hydroxylamine derivatives
SG11201401587QA (en) 2011-10-17 2014-07-30 Univ Johns Hopkins Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
EP3567031A1 (en) 2013-01-18 2019-11-13 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors with improved therapeutic index
EP3148983A1 (en) 2014-05-27 2017-04-05 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
WO2015183839A1 (en) 2014-05-27 2015-12-03 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives

Also Published As

Publication number Publication date
CA2852914A1 (en) 2013-04-25
CN108409662B (zh) 2021-10-26
MX2014004596A (es) 2014-09-04
JP2015501308A (ja) 2015-01-15
US20170050947A1 (en) 2017-02-23
KR102061537B1 (ko) 2020-01-03
BR112014009282B1 (pt) 2021-12-14
SG11201401587QA (en) 2014-07-30
AU2013201929B2 (en) 2015-07-23
US20140275134A1 (en) 2014-09-18
US20160115148A1 (en) 2016-04-28
JP6177246B2 (ja) 2017-08-09
BR112014009282A2 (pt) 2017-06-13
IL232101A (en) 2017-04-30
US9181213B2 (en) 2015-11-10
IL232101A0 (en) 2014-05-28
CA2852914C (en) 2019-11-26
CN108409662A (zh) 2018-08-17
AU2013201929A1 (en) 2013-05-02
EP2776402B1 (en) 2017-07-26
EP2776402A1 (en) 2014-09-17
CN104053647B (zh) 2018-06-01
HK1200168A1 (en) 2015-07-31
WO2013059194A1 (en) 2013-04-25
US9499511B2 (en) 2016-11-22
MX363306B (es) 2019-03-20
KR20140107197A (ko) 2014-09-04
CN104053647A (zh) 2014-09-17
US9862699B2 (en) 2018-01-09
AU2015246114A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
BR112014009282A8 (pt) ácido de meldrum, ácido barbitúrico e derivados de pirazolona substituída com hidroxilamina como doadores de hno
AU2018236800B2 (en) DNA-PK inhibitors
BR112017003312A2 (pt) compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos
BR112015003742A2 (pt) sistema de montagem de componente de descarga
BR112012030711A2 (pt) derivado de purinona
BR112014026703A2 (pt) inibidores de dna-pk
CR20130267A (es) Inhibidores de nampt y rock
EA201201648A1 (ru) Стимуляторы sgc
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
CL2016001543A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas.
BR112015004747A2 (pt) moléculas oligonucleotídicas de fita dupla para p53 e métodos de uso das mesmas
SV2010003705A (es) 2,6- diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
SV2011003901A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
EA201491866A1 (ru) Способ обработки волос
IN2012DN05025A (pt)
MX356796B (es) Derivados de hidroxilamina bis-acilados.
BR112014009006B8 (pt) Compostos heterocíclicos e métodos de uso dos mesmos
CL2017002660A1 (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)
FI20115135A (fi) Mikrofibrilloidun selluloosan tulehduksia estävä vaikutus
BR112018012590A2 (pt) formas cristalinas polimórficas do ácido obeticólico
BR112016006388A2 (pt) inibidor seletivo da fosfatidilinositol 3-quinase gama
BR112018011525A2 (pt) inibidores da tirosina quinase de bruton e métodos de seu uso
BR112016001978A2 (pt) derivados de ciclopentano 1,3-dissubstituído

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/10/2012, OBSERVADAS AS CONDICOES LEGAIS.